STOCKHOLM, October 20th, 2026 - In accordance with the resolution of the Annual General Meeting on May 21st, 2026, the Chairman of the Board has contacted the company's two largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company's two largest shareholders or group of shareholders have wished to appoint such representative, the third largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of three members, in accordance with the resolution of the Annual General Meeting on May 21st, 2026.
Moberg Pharma's Nomination Committee ahead of the Annual General Meeting for the fiscal year January - December 2026 comprises:
Together, the Nomination Committee represents 10,7 percent of the shares in Moberg Pharma as of September 30th, 2025.
The Nomination Committee shall submit proposals for the fiscal year January - December 2026 by the Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.
The Annual General Meeting for the fiscal year January - December 2026 will be held on May 20th, 2027.
Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to info@mobergpharma.se by April 1st, 2027.
For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se
About this information
The information was released for public distribution through the contact named above, on October 20th, 2026, at 8:00 am CET.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 14 countries. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. MOB-015 is sold in Sweden, Norway and Israel under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe, APAC, Canada and China. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).